Even after a plunge last month that wiped US$46 billion off Chinese healthcare stocks, domestic drugmakers might be far from their floor as a Beijing-led policy shift gathers pace.
China’s plan to drive down generic drug prices through a centralized bulk procurement program is set to redraw the industry by forcing its thousands of small generic drugmakers to streamline and consolidate after decades of enjoying outsized profit margins.
“There won’t be a second act for traditional generic drugmakers in China,” said Dai Ming (戴明), Shanghai-based fund manager at Hengsheng Asset Management Co (恒盛資產管理)
Photo: Reuters
“In the past, there was hope that these companies would benefit from more government investment in healthcare due to the aging population, but now these healthcare stocks will be further hurt by policy and undergo a greater correction,” Dai said.
To survive the shifting landscape and rely less on generics — drugs whose patents have expired — many companies are scrambling to pump money into research and development (R&D).
Discovering a new medicine allows companies to earn high profits for as long as the new drug is covered by a patent, balancing out the loss of revenue from the fall in generic drug prices.
Chinese companies had been in a sweet spot.
Among the top 100 generic drugmakers, Chinese firms had a 74 percent gross margin and an 18 percent profit margin in the third quarter of last year, compared with a global average of 55 percent and 9.5 percent respectively, according to data compiled by Bloomberg.
The privileged position was due to the quirks of China’s regulatory system. While multinational giants had to wait years for approval to import their new drugs, the domestic generic makers could do a thriving business in copying, testing and getting local permission for the medicines.
At the same time, the industry benefited because of the lack of a centralized system for quality control.
Multinationals like Pfizer Inc and AstraZeneca PLC could win more hospital tenders for their off-patent drugs, as they could more easily offer quality assurances for their higher-cost medicines. That kept prices elevated throughout the pharma sector.
Now, China has embarked on a pilot program in which major cities buy certain drugs in bulk, forcing companies to bid for contracts and driving prices down by an average of 52 percent, one by as much as 90 percent.
Chinese Vice Premier Sun Chunlan (孫春蘭) last week said that China would be expanding the program to cover more cities and drugs, as medicine prices must fall for healthcare to be affordable for the public.
Chinese companies that are already heavily invested in R&D stand the best chance of surviving the new landscape.
Among firms listed in China, Jiangsu Hengrui Medicine Co (恆瑞醫藥) has invested the most in research by far — amounting to 16 percent of revenue in the latest quarter. Guangzhou-based Yipinhong Pharmaceutical Co (一品紅藥業) is in second place with 8.4 percent. Zhejiang Jingxin Pharmaceutical Co (京新藥業), Chengdu Kanghong Pharmaceutical Group Co (康弘藥業) and Tianjin Lisheng Pharmaceutical Co (天津力生製藥) have each invested about 8 percent of sales into research.
Among Hong Kong-traded shares, CSPC Pharmaceutical Group Ltd (石藥集團) has 8.14 percent of sales invested in research and Sino Biopharmaceutical Ltd (中國生物製藥) has 6.23 percent.
Jiangsu Hengrui gets 20 percent of its revenue from novel drugs and 80 percent from generics, a ratio it wants to flip, Lianshan Zhang, president of global R&D, said in an interview last month.
However, a successful novel drug can take decades to develop, and the Chinese pharmaceuticals are up against the deep pockets and research talent of the multinationals, which are enjoying rapid approval from Chinese regulators for their new medicine.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
CROSS-STRAIT TENSIONS: The US company could switch orders from TSMC to alternative suppliers, but that would lower chip quality, CEO Jensen Huang said Nvidia Corp CEO Jensen Huang (黃仁勳), whose products have become the hottest commodity in the technology world, on Wednesday said that the scramble for a limited amount of supply has frustrated some customers and raised tensions. “The demand on it is so great, and everyone wants to be first and everyone wants to be most,” he told the audience at a Goldman Sachs Group Inc technology conference in San Francisco. “We probably have more emotional customers today. Deservedly so. It’s tense. We’re trying to do the best we can.” Huang’s company is experiencing strong demand for its latest generation of chips, called
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure